Equities research analysts forecast that Merck & Co., Inc. (NYSE:MRK) will report $12.02 billion in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Merck & Co., Inc.’s earnings, with the lowest sales estimate coming in at $12.01 billion and the highest estimate coming in at $12.04 billion. Merck & Co., Inc. posted sales of $12.40 billion in the same quarter last year, which would indicate a negative year over year growth rate of 3.1%. The company is expected to announce its next quarterly earnings results on Tuesday, November 3rd.
According to Zacks, analysts expect that Merck & Co., Inc. will report full-year sales of $47.81 billion for the current fiscal year, with estimates ranging from $47.40 billion to $48.22 billion. For the next fiscal year, analysts anticipate that the business will post sales of $50.84 billion, with estimates ranging from $47.84 billion to $53.14 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The company had revenue of $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. During the same period in the prior year, the business posted $1.30 EPS. The firm’s revenue was down 7.6% compared to the same quarter last year.
Several research firms have recently weighed in on MRK. Morgan Stanley reiterated a “buy” rating and set a $89.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. Wolfe Research downgraded Merck & Co., Inc. from an “outperform” rating to a “peer perform” rating in a report on Friday, June 12th. Royal Bank of Canada restated a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, August 4th. SVB Leerink lifted their price objective on Merck & Co., Inc. from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Finally, ValuEngine upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating in a report on Thursday. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck & Co., Inc. has an average rating of “Buy” and a consensus target price of $94.54.
In other news, EVP Julie L. Gerberding sold 36,285 shares of the business’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $80.00, for a total transaction of $2,902,800.00. Following the sale, the executive vice president now owns 62,862 shares in the company, valued at $5,028,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frank Clyburn sold 18,876 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $81.55, for a total value of $1,539,337.80. Following the sale, the executive vice president now owns 99,639 shares in the company, valued at approximately $8,125,560.45. The disclosure for this sale can be found here. Insiders have sold 65,541 shares of company stock worth $5,303,782 in the last 90 days. Insiders own 0.28% of the company’s stock.
Hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its position in Merck & Co., Inc. by 0.6% in the second quarter. BlackRock Inc. now owns 197,558,293 shares of the company’s stock valued at $15,277,182,000 after buying an additional 1,212,965 shares during the last quarter. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 0.7% during the 1st quarter. State Street Corp now owns 117,343,358 shares of the company’s stock worth $9,098,570,000 after purchasing an additional 849,474 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Merck & Co., Inc. by 1.2% during the 1st quarter. Janus Henderson Group PLC now owns 29,308,122 shares of the company’s stock worth $2,255,001,000 after purchasing an additional 353,907 shares during the period. Nordea Investment Management AB grew its holdings in shares of Merck & Co., Inc. by 89.9% during the 2nd quarter. Nordea Investment Management AB now owns 18,381,614 shares of the company’s stock worth $1,404,356,000 after purchasing an additional 8,699,890 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of Merck & Co., Inc. by 5.4% during the 1st quarter. Franklin Resources Inc. now owns 18,077,702 shares of the company’s stock worth $1,390,898,000 after purchasing an additional 933,775 shares during the period. Institutional investors and hedge funds own 73.18% of the company’s stock.
NYSE:MRK traded down $0.25 during midday trading on Tuesday, reaching $85.24. 8,923,680 shares of the stock traded hands, compared to its average volume of 7,422,512. The company has a fifty day moving average of $82.09 and a 200 day moving average of $79.32. Merck & Co., Inc. has a 12 month low of $65.25 and a 12 month high of $92.64. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.32. The stock has a market capitalization of $215.59 billion, a P/E ratio of 20.79, a PEG ratio of 2.22 and a beta of 0.45.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.61 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.86%. Merck & Co., Inc.’s payout ratio is 47.01%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
See Also: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.